Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Recombinant Proteins Research Group, The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Life Sci. 2022 Sep 15;305:120760. doi: 10.1016/j.lfs.2022.120760. Epub 2022 Jul 1.
Alcohol-associated liver disease (ALD) comprises a spectrum of liver diseases that include: steatosis to alcohol-associated hepatitis, cirrhosis, and ultimately hepatocellular carcinoma. The pathophysiology and potential underlying mechanisms for alcohol-associated liver disease are unclear. Moreover, the treatment of ALD remains a challenge. Intestinal microbiota include bacteria, fungi, and viruses, that are now known to be important in the development of ALD. Alcohol consumption can change the gut microbiota and function leading to liver disease. Given the importance of interactions between intestinal microbiota, alcohol, and liver injury, the gut microbiota has emerged as a potential biomarker and therapeutic target. This review focuses on the potential mechanisms by which the gut microbiota may be involved in the pathogenesis of ALD and explains how this can be translated into clinical management. We discuss the potential of utilizing the gut microbiota signature as a biomarker in ALD patients. Additionally, we present an overview of the prospect of modulating the intestinal microbiota for the management of ALD.
酒精性肝病（ALD）包括一系列肝脏疾病，包括：脂肪变性、酒精性肝炎、肝硬化，最终发展为肝细胞癌。酒精性肝病的病理生理学和潜在的潜在机制尚不清楚。此外，ALD 的治疗仍然是一个挑战。肠道微生物群包括细菌、真菌和病毒，现在已知它们在 ALD 的发展中很重要。饮酒会改变肠道微生物群和功能，导致肝脏疾病。鉴于肠道微生物群、酒精和肝损伤之间相互作用的重要性，肠道微生物群已成为潜在的生物标志物和治疗靶点。本综述重点介绍了肠道微生物群在 ALD 发病机制中的潜在作用机制，并解释了如何将其转化为临床管理。我们讨论了利用肠道微生物群特征作为 ALD 患者生物标志物的潜力。此外，我们还概述了调节肠道微生物群以管理 ALD 的前景。
